Angelini Pharma
Angelini Pharma, a prominent player in the pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and Latin America. Founded in 1919, the company has established itself as a leader in the development of innovative healthcare solutions, particularly in the fields of pain management, mental health, and consumer health products. With a diverse portfolio that includes prescription medications and over-the-counter products, Angelini Pharma is recognised for its commitment to quality and efficacy. The company’s unique approach combines scientific research with a deep understanding of patient needs, positioning it as a trusted name in the market. Notable achievements include significant advancements in therapeutic areas and a strong presence in both the pharmaceutical and consumer health sectors, underscoring its role as a key contributor to global health.
DitchCarbon Score
How does Angelini Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Angelini Pharma's score of 21 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Angelini Pharma's reported carbon emissions
In 2023, Angelini Pharma reported total carbon emissions of approximately 16,773,300 kg CO2e, with Scope 1 emissions accounting for about 16,773,300 kg CO2e and Scope 2 emissions at approximately 4,659,900 kg CO2e. This represents an increase in emissions from 2022, where the company recorded about 15,036,800 kg CO2e in Scope 1 and approximately 9,418,700 kg CO2e in Scope 2. The breakdown of Scope 1 emissions in 2023 includes mobile combustion emissions of about 1,549,700 kg CO2e, fugitive emissions of approximately 164,000 kg CO2e, and stationary combustion emissions of around 15,055,600 kg CO2e. For Scope 2, the total market-based emissions were approximately 6,204,900 kg CO2e. Currently, Angelini Pharma has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. As such, their climate commitments remain unspecified, indicating a potential area for future development in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 15,036,800 | 00,000,000 |
| Scope 2 | 7,677,500 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Angelini Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
